Who
can apply?
Amount and tenure of grants
GST
Adjudication process
Members of the Australian Physicians Independent
Committee (APIC)
Privacy of personal information
Your application
Conditions
The Cardiovascular Lipid Research Grants (CVL grants) are awarded for the purpose of furthering clinical research in the fields of cardiovascular disease including stroke, lipid disorders and associated areas. The proposals should exclusively involve clinical research in humans.
Applications are invited from Australian medical graduates who have entered the field of research (or returned after an appropriate break) within the last five years (e.g. the applicant has initiated or been awarded a PhD/MD from 2003 onwards). Applications will not be accepted from senior researchers including professors, associate professors, or CIAs for successful NH&MRC applications.
The principal applicant must be a citizen or permanent resident of Australia. Grant recipients must conduct the majority of the research within Australia.
Grants will be awarded for one year. Individual grants will be up to AUD$55,000 (including GST) per annum and will be awarded to cover part salaries, equipment, research materials and expenses. Equipment will only be funded if it is essential for the conduct of the research. Travel to conferences will only be funded to the value of AUD$1500.
Grant recipients must notify CVL of any other funding obtained (or applied for) for the duration of the CVL award.
For the year 2007, the CVL Research Grants Program has been included on the Australian Competitive Grants Register (ACGR), which contributes the income portion of the DETYA Higher Education Research Data Collection.
Back
to top
GST
Your application should include provision for GST on the entire amount
requested. If you are a successful applicant you will be required to provide
Pfizer Australia with a tax invoice inclusive of GST from your institution.
This tax invoice must include the institution’s ABN.
Back to top
Applications will initially be assessed for completeness. Incomplete applications will not be processed further.
Applications will be reviewed by two independent reviewers and by the Australian Physicians Independent Committee (APIC), which is composed of leading physicians and researchers from around the country. Pfizer Head Office in New York will also review proposals involving any Pfizer compounds. The APIC is responsible for independent objective evaluation and recommendations of funding proposals for research projects. All decisions of the APIC are final and no correspondence will be entered into.
If a grant is successful and Pfizer medicines or active substances are listed in the proposal, the supply of these drugs would be subject to normal company approval procedures for independent research grants.
Members of the CVL Australian Physicians
Independent Committee (APIC)
In 2007, the APIC comprises a core committee of three members:
Professor Lawrie Beilin, Royal Perth Hospital, WA (Chair)
Professor Andrew Tonkin, Monash University,
VIC
Professor Philip Barter, Heart Research Institute, NSW
Working closely with the core committee is the Advisory Panel, which is composed of the following leading physicians and researchers from around Australia:
Professor Mark Cooper, Baker Research Institute,
VIC
Dr David Cross, Royal Brisbane Hospital, QLD
Professor Stephen Davis, Royal Melbourne Hospital, VIC
Professor Graeme Hankey, Royal Perth Hospital, WA
Professor Leon Simons, St Vincents Hospital, NSW
Ass/Prof Richard O’Brien, University of Melbourne, VIC
Professor Stephen Hunyor, Royal North Shore Hospital, NSW
Professor David Kaye, Baker Heart Research Institute, VIC
Dr Margaret Arstall, University of Adelaide, SA
Administrative support will be provided by the CVL Secretariat, which is comprised of Medical/Scientific staff from Pfizer Australia.
Privacy of personal information
All personal information provided in your application, project summary and assessment details will be kept by the CVL Secretariat, Pfizer Australia Pty Ltd and used only for the purposes of administering this application, and, if successful, the grant. Your personal information will be disclosed to reviewers as noted above. You have the right to access your personal information at any time. If you wish to do this, please contact Pfizer Australia using the details provided on the ‘Contact us’ page.
If you have any questions regarding the completion of the application form please contact the CVL Secretariat.
The application and attachments indicated must be presented on the CVL application form.
Applicants are required to complete their applications electronically in a minimum size of 12-point font; using the template provided. Please provide one original (printed single sided) and two hard copies, which may be double sided and an electronic version of the application and your CV (Microsoft Word format) either on a disc or via email.
Send the completed application to:
Ms Kathryn Watts
Secretariat
Cardio Vascular Lipid Research Grants (Pfizer Australia)
38-42 Wharf Road
West Ryde NSW 2114
Contact details:
Phone: (02) 9850 3771
Email: cvlgrants.australia@pfizer.com
Fax: (02) 9850 3131
Required documents
Applicants must supply one original
and two hard copies of each of the following:
• Completed application form
• Study proposal
• CV (principal investigator only)
• Publication list
• Human Research Ethics Committee approval letter, if applicable. Funding will not be granted until
the ethics approval letter has been received by the CVL Secretariat.
• A letter from the supervisor or department head supporting the project.
Successful applicants of grants involving the use of Pfizer compounds will be required to sign a Clinical Trial Agreement (CTA).
CVL Research Grants are awarded with the expectation that timely submissions for presentation will be made at appropriate medical meetings or research forums and that papers will be submitted for publication in appropriate peer-reviewed medical journals. A copy of all published papers must be sent to the CVL Secretariat. Furthermore, CVL will be acknowledged for sponsoring the research.
It is a requirement of CVL that protocols that receive funding are not altered following the review process.
Twelve months after receiving funds, grant recipients will be required to provide a 500-word research summary to the CVL Secretariat.
CVL reserves the right to publicise the names of the grant recipients, their institutions, titles and summaries of their research projects, following consultation with the APIC.
All decisions of the APIC are final.
Applications closed on 23 May 2008.
